| HOME >> BIOLOGY >> TECHNOLOGY |
RADNOR, Pa., Aug. 23 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:
Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of all purchasers of securities of GPC Biotech AG (Nasdaq: GPCB) ("GPC" or the "Company") from December 5, 2005 through July 24, 2007, inclusive (the "Class Period").
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin Barroway Topaz & Kessler, LLP (Darren J. Check, Esq. or Richard A. Maniskas, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@sbtklaw.com.
The Complaint charges GPC and certain of its officers and directors
with violations of the Securities Exchange Act of 1934. GPC is a
biopharmaceutical company engaged in the discovery, development and
commercialization of new drugs to treat cancer. More specifically, the
Complaint alleges that the Company failed to disclose and misrepresented
the following material adverse facts which were known to defendants or
recklessly disregarded by them: (1) that the U.S. Federal Drug
Administration ("FDA") had previously expressed disapproval regarding the
Company's choice of methodology and a primary endpoint in the satraplatin
studies; (2) that the Company continued to evaluate satraplatin using the
disputed endpoint; (3) that the Company disregarded the FDA's previously
expressed concerns about the disputed primary endpoint, and submitted the
satraplatin study results to the FDA with the disputed primary e
'/>"/>
| SOURCE Schiffrin Barroway Topaz & Kessler, LLP Copyright©2007 PR Newswire. All rights reserved |